Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Curigliano G, De Braud F, Teresa Sandri M, Renne G, Zorzino L, Scardino E, Rocco B, Spitaleri G, De Pas T, Noberasco C, Nolè F, Verweij F, Matei V, De Cobelli O.
Curigliano G, et al. Among authors: de braud f, de pas t, de cobelli o.
Anticancer Drugs. 2007 Sep;18(8):949-54. doi: 10.1097/CAD.0b013e328136c162.
Anticancer Drugs. 2007.
PMID: 17667601
Clinical Trial.